Gilead Sciences (NASDAQ:GILD) Lifted to “Overweight” at Wells Fargo & Company
Wells Fargo & Company upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note released on Monday morning, Marketbeat reports. The firm currently has $100.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $78.00. Other equities analysts […]
More Stories
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...